Unique ID issued by UMIN | UMIN000033538 |
---|---|
Receipt number | R000038242 |
Scientific Title | A clinical study for evaluating the safety of excessive consumption of saw palmetto extract. |
Date of disclosure of the study information | 2019/10/02 |
Last modified on | 2018/12/21 16:30:24 |
A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.
A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.
A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.
A clinical study for evaluating the safety of excessive consumption of saw palmetto extract.
Japan |
No
Adult |
Others
NO
To evaluate the safety of excessive consumption of saw palmetto extract
Safety
Doctor's questions, Physical measurement, Physical examination, Blood test, Urinalysis, Adverse event
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Food |
Saw palmetto extract, 4 weeks excessive consumption
20 | years-old | <= |
64 | years-old | >= |
Male and Female
(1) Healthy males and females aged 20 to 64 years-old.
(2) Subjects who can make self-judgment and are voluntarily giving written informed consent.
(1) Subjects who were diagnosed with serious disease (e.g., liver disease, kidney disease, digestive disease, heart disease, and/or peripheral vascular disease).
(2) Subjects with abnormal parameters in liver and/or kidney function.
(3) Subjects who had a gastrointestinal surgery.
(4) Subjects with a disease currently under treatment.
(5) Subjects with anemic.
(6) Subjects who play high intensity sports and/or are on a diet.
(7) Subjects who can't stop using functional foods (including Food for Specified Health Uses or Foods with Function Claims) and/or Specified quasi-drugs during the current study periods.
(8) Subjects who are under treatment with medications (including OTC or prescribed medication).
(9) Subjects who drink excessive alcohol, or who can't stop drinking from one day before each measurement.
(10) Subjects who are planning to become pregnant after imformed consent for the current study, pregnant or lactating.
(11) Subjects who are participating in other studies or planning to participate during the current study period.
(12) Subjects who are judged as unsuitable for the current study by the investigator for other reasons.
22
1st name | |
Middle name | |
Last name | Naoki Miura |
Miura Clinic, Medical Corporation Kanonkai
Internal Medicine
Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka, Japan
06-6135-5200
mterashima@miula.co.jp
1st name | |
Middle name | |
Last name | Makoto Terashima |
Oneness support Co., Ltd.
Clinical trial Division
Higashitenma building 4F, 1-7-17, Higashitenma, Kita-ku, Osaka, Japan
06-4801-8917
mterashima@oneness-sup.co.jp
Oneness support Co., Ltd.
BGG Japan Co., Ltd.
Profit organization
NO
2019 | Year | 10 | Month | 02 | Day |
Unpublished
Completed
2018 | Year | 07 | Month | 23 | Day |
2018 | Year | 07 | Month | 30 | Day |
2018 | Year | 07 | Month | 27 | Day |
2018 | Year | 12 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038242